Detalhe da pesquisa
1.
Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
Ann Oncol
; 34(10): 833-848, 2023 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-37597580
2.
Inclusion, diversity, equity, and access (IDEA) in gynecologic cancer clinical trials: A joint statement from GOG foundation and Society of Gynecologic Oncology (SGO).
Gynecol Oncol
; 174: 278-287, 2023 07.
Artigo
Inglês
| MEDLINE | ID: mdl-37315373
3.
Immunotherapy toxicities: An SGO clinical practice statement.
Gynecol Oncol
; 166(1): 25-35, 2022 07.
Artigo
Inglês
| MEDLINE | ID: mdl-35597686
4.
Hormone therapy (HT) in women with gynecologic cancers and in women at high risk for developing a gynecologic cancer: A Society of Gynecologic Oncology (SGO) clinical practice statement: This practice statement has been endorsed by The North American Menopause Society.
Gynecol Oncol
; 157(2): 303-306, 2020 05.
Artigo
Inglês
| MEDLINE | ID: mdl-32067815
5.
BRCA1- and BRCA2-related mutations: therapeutic implications in ovarian cancer.
Ann Oncol
; 24 Suppl 8: viii22-viii27, 2013 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-24131965
6.
Phase II study of bevacizumab with liposomal doxorubicin for patients with platinum- and taxane-resistant ovarian cancer.
Ann Oncol
; 23(12): 3104-3110, 2012 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-22851407